Empowered Patient Podcast cover image

Empowered Patient Podcast

Latest episodes

undefined
Jun 12, 2025 • 22min

Using an AI Assistant to Expand Primary Care Access and Reduce Physician Burnout with Dr. David Carmouche Lumeris

Dr. David Carmouche, Chief Clinical Transformation Officer at Lumeris, is addressing the primary care shortage by providing a platform that supports primary care physicians in managing a broader patient population and delivering better health outcomes. The Lumeris platform, Tom, is an AI-powered virtual assistant that can interact with patients, provide chronic disease management, education and support, and coordinate care on behalf of providers. Tom can improve efficiency, reduce clinician burnout, and provide more convenient and personalized experiences for patients.  David explains, "And so, they built the company, Lumeris, as a commercialization arm of their relationship to empower other primary care physicians to manage populations and deliver better health outcomes at a lower cost. And so for the last 12 years or so, Lumaris has been partnering largely with large medical groups and health systems to help them manage populations, Medicare, Medicaid, and commercial populations, and helping drive high performance and high outcomes within those relationships. The economics are shared economics, so when the plans and providers are successful by delivering better outcomes, Lumeris shares in those rewards."  "Given the 20-year history that I mentioned of understanding care deeply as a provider of care and as a partner to those providers of care, we have the fortune to build new technology to support primary care. Our environment starts with aggregating data, and that data helps us define a view of a patient. That data could come from an electronic medical record, it could come from claims data from a pharmacist, it could come from claims data from a payer, or it could come from a pharmacist or a lab. It could be consumer data that is purchasable, as organizations like Target, Walmart, and others use to market to us today. We aggregate that data to create a 360° view of a patient. Then we're able to leverage some of the new artificial intelligence that creates the ability for the platform to interact with patients on behalf of their clinical care teams at points in time where we understand that there is a defined next best clinical action that might help you in your health journey." #Lumeris #MedAI #DigitalHealth #PrimaryCareProviders lumeris.com Download the transcript here
undefined
Jun 11, 2025 • 20min

Transforming and Expanding Supportive Care Services with Jeff Bennett Modivcare

Jeff Bennett, Chief Strategy and Innovation Officer at Modivcare, is addressing and expanding supportive care services to provide transportation, personal care services, and remote patient monitoring. A lack of transportation leads to missed appointments and therapies, necessitating a coordinated approach to support vulnerable populations. Modivcare utilizes remote sensors and AI to enhance human engagement and coordination, and is designed to be both preventative and predictive, keeping patients healthy and out of the hospital.  Jeff explains, "Modivcare works on behalf of health plans, states, and risk-based entities. We provide supportive care services that meet the needs and address the needs of patients. One of those services is transportation, so non-emergency medical transportation. We also provide personal care services, which support members with activities of daily living, like bathing, meal preparation, and such. And then finally, I lead the monitoring organization, which provides services to monitor members or patients at home so they can live and age at home on their own." "The biggest need, at the top, is that our members have health-related social needs or SDOH needs. They also are living with chronic conditions, so they need supportive care services that not only provides that core service -- so there's the obvious "I need a ride" or "if I press the button because I've fallen and I need 911 to be called if I need an ambulance or my caregiver or family member to come help me." But most importantly, the services that they need are providing an engagement service. Really, what we provide is a supportive care service that drives human connection through cutting-edge technology that drives continuous engagement. They always know that we're here, and we listen to them. We understand their needs and try to address those needs, which could be healthcare-related, social-related, or simply loneliness. So it spans that broad spectrum. And any one of our services, we're delivering that core service, but we're also driving engagement and listening for what else the member needs." #Modivcare #SDOH #SupportiveCareServices #MedAI #DigitalHealth #CareCoordination modivcare.com Download the transcript here
undefined
Jun 10, 2025 • 25min

Focus on Resistance Pathways to Target Blood Cancers and Graft-Versus-Host Disease with Peter Ordentlich Syndax Pharmaceuticals

Peter Ordentlich, Chief Scientific Officer and Founder at Syndax Pharmaceuticals, a clinical oncology company, is focused on developing precision medicine approaches to treat cancer and chronic graft-versus-host disease. The menin protein plays a critical role in driving certain types of blood cancers, and the Synex therapy is a menin inhibitor that can disrupt this cancer-driving pathway. The platform is also developing an antibody addressing the unmet needs in cGVHD to reduce the disease-driving macrophages. Peter explains, "Syndax is a clinical oncology company, which means we're focused primarily on cancer, and we're primarily doing clinical development. We started the company really looking at resistance pathways to developing cancer, and we've been focused on two main areas. One in the indication space of leukemia, which are certain types of blood cancers, and that's with a program we have around the small molecule drug called revumenib. We are also focused in another area of diseases called chronic graft-versus-host disease. These are diseases that happen post-stem cell transplant, and there we're developing an antibody called axatilimab. And so those two programs are really what we've been focusing on for the last five or six years and have led to each of those drugs." "So menin is a very interesting protein, and basically what this is, it's called a scaffold protein. And you can imagine a scaffold, just something you build things upon. And so menin interacts with DNA through a variety of other factors, and you build on top of this a complex of other proteins that can turn genes on and off. And in the case of certain types of leukemias, the mutation that creates certain other cancer-causing proteins binds to menin. That's what drives certain genes that drive leukemia to always be turned on. And so what we've tried to do and others have tried to do is disrupt that interaction and essentially cause the scaffold to fall apart. And when that falls apart, you can no longer keep those genes on that drive leukemia, and instead, you have genes that essentially cause the cell to stop growing."  #SyndaxPharma #AcuteLeukemia #cGHVD #Oncology #PrecisionMedicine #Menin #MeninInhibitors syndax.com Download the transcript here
undefined
Jun 9, 2025 • 22min

Bringing Together Doctors to Fill the Need for Trusted Health Information with Vikram Bhaskran and Dr. Rohan Ramakrishna Roon

Vikram Bhaskran, CEO and Co-Founder, and Dr. Rohan Ramakrishna, Chief Medical Officer and Co-Founder of Roon, have taken on the mission to provide trustworthy and personalized medical information to patients and caregivers. Leveraging technology and the expertise of medical professionals, Roon has created a comprehensive resource for navigating medical challenges. They emphasize the importance of addressing misinformation and providing accurate, science-based information. The platform is not intended to replace doctors, but to supplement relevant information and enable better communication with healthcare providers and improve patient outcomes. Vikram explains, "Our mission is to be the best place online for anyone navigating any health condition. I started the company really through my own journey as a caregiver to my dad, who had ALS. And in that journey, I had two insights. One is that the biggest tech companies fail us. And in this moment of crisis, most people navigating any health condition will turn to "Doctor Google" and Facebook groups, which can be an overwhelming experience. And so I felt we could do better as someone coming from the tech world. I was at Pinterest before this, and my second insight was that there's a finite number of doctors. And so the experience of health today for really anyone is that you spend a ton of time in waiting rooms. You spend a ton of time waiting for someone to answer your health questions. And so Roon was born out of those two insights. And our goal is to be the best online platform to scale the world's best medical experts and their knowledge." Rohan elaborates, "The doctors are from more than 70 different academic medical institutions, and the number is growing. They represent all the experts who have expertise to share alongside the health journeys we've launched. So as of today, we've launched brain cancer, ALS, dementia, Fertility and Family Building, PCOS, endometriosis, menopause, and we are soon to launch several other conditions related to women's health, including gynecological health. Our experts span the doctors you would expect, such as oncologists, neurologists, and OBGYNs, among others, but also social workers, physical therapists, occupational therapists, speech therapists, and legal and financial counselors - really anyone who has real expertise that they can lend to the experience of a journey. So much of dementia care, for example, is not driven by your neurologist, but by the experience of caring for someone who needs help, whether it's at a memory care facility or a skilled nursing facility, dealing with issues that doctors typically don't have a great answer for."  #Roon #HealthcareInformation #MedAI #HealthcareOutcomes #DigitalHealth roon.com Download the transcript here
undefined
Jun 6, 2025 • 22min

Next Generation Monoclonal Antibodies for Inflammatory Respiratory Diseases with Barry Quart Connect Biopharma

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Download the transcript here
undefined
Jun 5, 2025 • 22min

Scalable MSC Platform Enabling Next Wave of Stem Cell Therapies with Dr. Kilian Kelly Cynata Therapeutics

Dr. Kilian Kelly, Chief Executive Officer and Managing Director of Cynata Therapeutics, has taken on the challenge of manufacturing stem cell therapies consistently and at scale in order to drive the advancements necessary for the next generation of regenerative medicine. Cynata is employing a novel approach that utilizes a single source of pluripotent stem cells (iPSCs) and mesenchymal cell ancestors (MCAs) to generate mesenchymal stem cells (MSCs). Lead programs are targeting graft-versus-host disease, osteoarthritis, and diabetic wounds, where clinical trials have shown great promise to treat these and other diseases. Kilian explains, "We're a stem cell regenerative medicine company, and what we're trying to do is to change the way that we can manufacture stem cell therapies in a consistent and scalable way. I'm sure many of your listeners have heard about stem cell therapies of various types. The particular type of cells that we're working on are called mesenchymal stem cells or MSCs. They've shown lots of promise for lots of different purposes, but a real challenge has been making these cells consistently, especially when you try to do that at a large scale. We have a unique novel manufacturing platform, which helps us to address that major challenge." "The way that these cells were historically produced and indeed still are produced in most cases is by harvesting cells from, for example, somebody donating bone marrow or adipose tissue, also known as fat. And those approaches have certainly allowed a lot of early-stage clinical trials to be performed, which showed lots of really exciting results. But often what happens is that when you move to a larger scale using such a process, and you try to make much larger quantities of cells, perhaps using many different donors, you start to see a lot of inconsistency. There are a few reasons for this. When you have inconsistency with a product, it's inevitable that you're going to get inconsistent results." "If you have inconsistent results in a clinical trial, it becomes a bit of a lottery, and sometimes you can have very disappointing results that are hard to explain. So we think that's been a really big issue that has caused a lot of problems in the field. And aside from the impact on clinical trial results, we also need to think about the future when these products are available and on the market, and how you can actually, in practical terms, produce enough of these products. So, in a nutshell, I think that is probably the major challenge that the field has faced."  #CynataTherapeutics #StemCellTherapy #RegenerativeMedicine #iPSCs #MSCs #MCAs Cynata.com Download the transcript here  
undefined
Jun 4, 2025 • 24min

Digital Tools for Caregivers and Patients to Navigate Challenges of Aging with Shauna Sweeney tendercare

Shauna Sweeney, Founder of tendercare, aims to assist caregivers with digital tools and expert support to simplify the process of caring for an aging family member. Recognizing the essential role of caregivers in the quality of life of the patient, tendercare provides a user-friendly interface that incorporates data from wearables and remote sensors to identify early warning signs of risks, help coordinate care, and encourage proactive preparation. The Magic Magnet feature allows caregivers and emergency responders to quickly update and share critical health information.  Shauna explains, "This is not just a gendered issue. We have 54 million just Americans, if we keep it to the US, who are currently providing unpaid family care. This usually takes the form of anything from looking through bills, managing medications, renewing prescriptions, coordinating doctors’ visits, and all other visits. Often, we find that those who are on our platform are the eldest child. So whether that's a daughter or a son, this is the type of person who is often leaning in to help. What is generally a parent or a grandparent who may or may not have the ability or the means to be able to get themselves to the doctor's appointments or pick up their prescriptions themselves, for instance." "Up until now, a lot of this has actually been human-powered. So, sitting down at the kitchen table with Mom and going through the mail to determine what needs to be paid by what time, but increasingly, because so many of us are living farther apart from one another, this is becoming more and more complicated. There is a level of coordination that we're all doing with one another, but we're often doing it over text. We're doing it over email, we're doing it over shared accounts and passwords. And so it's getting a lot more complicated, which is really where tendercare dropped in to try and help simplify a lot of this experience that so many of us are walking through right now."  #Trytendercare #DigitalHealth #CareGiving #CareGivingTech #SmartCare #AginginPlace #HealthEquity trytendercare.com Download the transcript here
undefined
Jun 3, 2025 • 19min

How Behavioral Economics is Transforming Healthcare Engagement with Karen Sussman Horgan VAL Health

Karen Sussman Horgan is the Co-Founder and CEO of VAL Health, a behavioral economics consulting firm that helps healthcare organizations drive engagement and nudge patients to improve their health and lifestyle choices. Behavioral economics is the science of understanding how patients make irrational choices based on biases, fear, and faulty analysis of outcomes and risk. Nudges can be carrots or sticks, but in healthcare, the focus is on making the right path easier to follow, reducing friction, and introducing positive reinforcements rather than penalties. Karen explains, "We work across the entire healthcare ecosystem. We think about digital health companies, how do you drive enrollment and engagement, and how do you optimize the journey? There are communications for that. We do a lot of work with payers, which is closing gaps in care, but also just improving the member experience in general with providers. It could be around provider adoption of new care pathways, but it's also about population health. We work with employers on wellness programs and pharma on that adherence. So think about where information alone isn't driving people to think about their health or take care of themselves. We create the nudges to help make that happen." "It's the science of understanding that we as humans are irrational. We have a bias toward the present. We have an aversion to loss and regret. We overweight probability. There are dozens of known biases, and what we do is harness them rather than asking people to change their biases. So let me give you a few examples to bring this to light because right now people are probably like, What is a bias? So think about Netflix when you watch an episode. First of all, you have choice overload when you get there. So it's giving you recommendations, but it also defaults you into the next episode because it plays on the fact that we have a status quo bias, and we're lazy, and we're just going to sit there and binge-watch. " #VALHealth  #BehavioralEconomics #BehavioralScience #BehaviorChange #DigitalHealth #Payers #HealthcareInnovation #HealthcareConsulting valhealth.com Download the transcript here  
undefined
Jun 2, 2025 • 21min

Transforming Provider Engagement by Using Comprehensive Data with Christine Lee AnalyticsIQ

Christine Lee, Head of Health Strategy and Partnerships at AnalyticsIQ, focuses on helping healthcare brands and pharmaceutical companies better understand and engage with healthcare providers by taking into account data beyond their professional lives. This data-driven Provider as a Person approach analyzes the healthcare professional's personal characteristics, outside interests, decision-making style, and preferred method of communication. The goal is to foster more meaningful relationships with providers, address provider burnout, and improve patient outcomes.   Christine explains, "We're coming into play here in supporting healthcare brands and better understanding the providers as people. As I mentioned, we're a people-based data company. I'd say that in an era where data is abundant and there is no shortage of health data being gathered and analyzed. So, you've got a lot of data assets out there that are coming from clinical trials, your real-world evidence, claims data, your electronic health records, all of which give insight into the aspects of a provider from a clinical setting. Traditionally, healthcare providers have been viewed primarily through the lens of their professional lives, their specialties, their role in patient care, prescription-writing behaviors, and even their affiliations. And these are super important factors. We do see those truly as table stakes, but they paint an incomplete picture."   "Providers, like patients, have unique lives, needs, and preferences, which really shape how they interact with the work they do and the brands they seek to engage with. The industry is really recognizing these nuances, which presents a unique opportunity for healthcare brands to acknowledge the complexity of the providers' lives beyond what you could say are their white coat moments, and differentiate their message. And so this can dig into driving more meaningful engagement. And for us here at AnalyticsIQ, we're focused on helping to understand healthcare providers, or HCPs, more broadly, and understanding some of their personal characteristics. So, the data we're bringing to the table to complement all the other data in the ecosystem will be things like considering their work-life balance." #AnalyticsIQ #HealthcareData #HealthcareAnalytics #HealthTech #HCPengagement #PatientExperience #ValueBasedCare #PersonalizedCare #HealthEquity #SDOH #HealthcarePrivacy #PatientData analytics-iq.com Download the transcript here
undefined
May 29, 2025 • 20min

Addressing the Skin Microbiome with Topical Engineered Microbes with Francisco Salva Azitra

Francisco Salva, President and CEO of Azitra, Inc., is leveraging the microbial bacteria that comprise the skin microbiome and exploring novel methods to deliver precision medicines to the skin. Azitra has genetically engineered specific strains of these microbes to produce proteins that are missing in patients with skin conditions like Netherton syndrome and cancer therapy-associated rashes. These bacterial strains have the ability to get beneath the stratum corneum and turn into miniature factories to make the therapeutic proteins and help the skin return to homeostasis. Francisco explains, "We're leveraging the billions of microbial bacteria that naturally live on us and are synergistic with our skin to help keep our skin in homeostasis or a regulated standard of existence. These bacteria makeup that are known as the skin microbiome, we have built up a library of these microbial bacteria strains commonly found on normal people and characterize them in a way that allows us to look for specific strains that may be able to deliver special proteins that may be missing or aberrantly made in the skin."   "What we're leveraging is that microbial strain’s ability to get past the outer protective layer of the skin called the stratum corneum. And these microbial strains get through that outer layer through intermittent spaces between the hair and that outer skin layer, the stratum corneum, and are able to get underneath the stratum corneum, grow, multiply, and colonize. And so by genetically engineering specific strains of these microbes, we're able to synthetically, or also known as recombinantly, make proteins that are missing in the patient's skin." "It's a little bit newer than the gut microbiome, and the field of study is also a little bit newer. And so the development of the understanding of the microbiome, which is what they call the defined consortia of various strains that normally live on us, is not quite as well elucidated as it is in the gut microbiome. That said, our mission at Azitra isn't to try to reset the entire regulation of the entire skin microbiome, but really just leverage specific strains of these bacteria that have the ability to get underneath that external layer of the skin."   #RareDisease #OrphanDisease #Dermatology #SkinDisease #SkinDisorder #PrecisionsMedicine #PrecisionDermatology #PrecisionDerm #Netherton #NethertonSyndrome #Ichthyosis #CancerRash #EGFRiRash  #EGFRiTreament azitrainc.com Download the transcript here

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app